BRAF and thyroid gland carcinoma: Starting from their primary application in melanoma cancer patients with BRAFV600E mutation, in which high efficiency in tumor growth inhibition had been initially observed [26,27], the possibility of exploiting BRAF inhibitors has been extended also to thyroid cancer patients.